The pathogenesis and treatment of asthma involve receptors. Receptors are responsible for asthma. These receptors produce inflammatory mediators that constrict the airways. Medications for asthma target these receptors. These receptors are targeted by beta-agonists, anticholinergics, and leukotriene modifiers. These medications reduce asthma attacks and symptoms. As a result, asthma receptor research and drug development have the potential to save millions of lives. Treatments for asthma target the beta-2 and muscarinic receptors. Asthma medications that target leukotriene and interleukin receptors are now available. Clinical and experimental studies suggest that modifying these receptors could result in the development of novel asthma treatments. To surmount asthma medication resistance, novel receptors or subsequent signalling cascades must be targeted. Research on asthma should investigate receptor-signaling pathway connections. Complex biological interactions can contribute to the development of new therapies and individualised care. Biomarkers for patient categorization and treatment response will be investigated. If biomarkers could predict treatment response, personalised medicine would progress. Clinicians could tailor treatment plans to enhance outcomes and reduce expenses. Personalised biomarkers with personalised medicine, genetic polymorphisms and inflammatory biomarkers can enhance asthma treatment. Mechanisms of drug resistance and novel asthma treatments are investigated. Dual-targeted therapies and GRK inhibitors could enhance treatment outcomes. Receptors contribute to the aetiology and treatment of asthma. Despite industry advances, many concerns persist. Complex asthma processes and novel treatments require further study. Asthma management and therapy present numerous challenges and opportunities for research. Addressing these concerns enhances asthma treatment. Research on asthma management and treatment should address these challenges and opportunities.